新型 2 型糖尿病治疗药物第 1 部分 - 注射用胰岛素。

New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 - Injectable Insulins.

机构信息

Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis; Department of Family Medicine, University of Tennessee Health Science Center, Memphis.

Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis.

出版信息

Am J Med. 2018 Jul;131(7):752-754. doi: 10.1016/j.amjmed.2018.01.049. Epub 2018 Feb 26.

DOI:10.1016/j.amjmed.2018.01.049

PMID:29496503

Abstract

The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

摘要

美国食品和药物管理局最近批准了几种新的胰岛素产品和现有胰岛素产品的新配方。这些新产品可能比旧产品具有优势，例如夜间低血糖风险较低和剂量方便；然而，它们价格昂贵。这是一系列文章中的第一篇，本篇综述将描述这些新胰岛素产品的潜在优缺点。